Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing investigational therapies that modulate immune pathways for cancer and immune-mediated diseases. Its primary emphasis is on ITK inhibition through its lead product candidate, soquelitinib, an oral small molecule designed to selectively target interleukin-2-inducible T cell kinase, influencing T cell differentiation and function. This approach aims to address conditions such as peripheral T cell lymphomas, atopic dermatitis, autoimmune lymphoproliferative syndrome, and other inflammatory disorders by promoting Th1 immune responses while suppressing Th2 and Th17 pathways. The company also advances other immune modulators, including ciforadenant, an A2A receptor antagonist for metastatic renal cell cancer, and mupadolimab, a monoclonal antibody for non-small cell lung cancer, often in combination with checkpoint inhibitors. Founded in 2014 and headquartered in South San Francisco, California, Corvus Pharmaceuticals Inc. operates through clinical trials, strategic collaborations like those with Angel Pharmaceuticals for greater China, and preclinical programs targeting adenosine pathways and CXCR2. It plays a specialized role in immuno-oncology and immunology within the biopharmaceutical sector.